mRNA vaccine maker Moderna (MRNA) has undoubtably been one of 2020’s success stories. One of the frontrunners in the race to develop a COVID-19 vaccine, investors have cheered each step of its candidate’s progress. While shares haven’t soared as majestically as those by some of its smaller sized peers, they have nevertheless appreciated by 243% so far this year.Yet, the company sparked confusion among investors last week after announcing that the US government has put an order in for 100 million doses of the company’s COVID-19 vaccine candidate mRNA-1273, for a total cost of $1.53 billion. As it turns out, …read more
Source:: Yahoo Finance
